Last 2.25 GBp
Change Today 0.00 / 0.00%
Volume 897.6K
VRP On Other Exchanges
Symbol
Exchange
London
As of 11:30 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

verona pharma plc (VRP) Snapshot

Open
2.25 GBp
Previous Close
2.25 GBp
Day High
2.25 GBp
Day Low
2.25 GBp
52 Week High
10/30/13 - 5.64 GBp
52 Week Low
07/23/13 - 1.66 GBp
Market Cap
22.7M
Average Volume 10 Days
1.1M
EPS TTM
-0.0075 GBp
Shares Outstanding
1.0B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERONA PHARMA PLC (VRP)

Related News

No related news articles were found.

verona pharma plc (VRP) Related Businessweek News

No Related Businessweek News Found

verona pharma plc (VRP) Details

Verona Pharma plc, a biotechnology company, engages in the research, discovery, and development of therapeutic drugs in the United Kingdom and Canada. The company develops drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary diseases (COPD), and cough. Its lead drug compound include RPL554, a bronchodilator/anti-inflammatory drug that is in Phase II clinical trial to treat asthma and COPD. The company is also developing VRP700, an anti-tussive drug, which is in Phase II clinical trial for the treatment of cough, as well as novel anti-inflammatory polysaccharides (NAIPs) to treat respiratory and inflammatory diseases. It has research and development agreements with King's College London and the University of British Columbia, as well as with Glycomar Limited and Glycores 2000 S.r.l. for its NAIPs programs. The company was founded in 2004 and is based in London, the United Kingdom.

12 Employees
Last Reported Date: 06/20/13
Founded in 2004

verona pharma plc (VRP) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 89.1K GBP
Executive Director and Member of Audit Commit...
Total Annual Compensation: 55.5K GBP
Compensation as of Fiscal Year 2012.

verona pharma plc (VRP) Key Developments

Verona Pharma plc Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 10:40 AM

Verona Pharma plc Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 10:40 AM. Venue: One Avenue De Lafayette, Boston, MA 02111, United States.

Verona Pharma plc Reports Unaudited Earnings Results for the Six Months Ended June 30, 2013

Verona Pharma plc reported unaudited earnings results for the six months ended June 30, 2013. For the period, the company’s operating loss was £1,308,902 against £1,075,557 a year ago. Loss before taxation was £1,307,027 against £1,062,731 a year ago. Total comprehensive loss for the period was £1,017,627 or 0.31 pence basic and diluted per share against £1,062,731 or 0.35 pence basic and diluted per share a year ago. Net cash outflow from operating activities was £1,291,199 against £1,183,937 a year ago. Purchase of plant and equipment was £1,197 against £9,623 a year ago. Payment for patents was £45,204.

Verona Pharma plc Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-12-2013 01:00 PM

Verona Pharma plc Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-12-2013 01:00 PM. Venue: Apella, 450 East 29th Street, New York, NY 10016, United States. Speakers: Sven Jan-Anders Karlsson, Chief Executive Officer and Executive Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRP:LN 2.25 GBp 0.00

VRP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VRP.
View Industry Companies
 

Industry Analysis

VRP

Industry Average

Valuation VRP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERONA PHARMA PLC, please visit www.veronapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.